Navigation Links
At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
Date:10/22/2013

Mekinist in patients harboring the BRAF V600K mutation.

"Interestingly, almost 50 percent of surveyed U.S. medical oncologists indicated they would prescribe Tafinlar or Mekinist in BRAF-mutated unresectable/metastatic malignant melanoma in patients who had progressed on a first-line of Zelboraf," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "This use of Tafinlar and Mekinist arises despite only provisional evidence to suggest Tafinlar exhibits efficacy following treatment with Zelboraf. Moreover, Mekinist is specifically not indicated for treatment of patients who have progressed on prior BRAF-inhibitor therapy."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
2. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
3. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
4. Users of PediaVisions Spot Vision Screener Honor Childrens Eye Health and Safety Month with Back-to-School Screenings
5. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
6. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
7. For Multiple Sclerosis Treatment, Prescriber Base for Genzymes Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
8. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
9. ALK Partners with AAFA to Launch New Online Resource for Allergic Patients During Allergy & Asthma Awareness Month
10. Pro-Dex, Inc. Announces Fiscal Third Quarter And Nine-Month Results
11. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... SUNNYVALE, Calif., May 1, 2015 Pharmacyclics, Inc. ... results for the quarter ended March 31, 2015, as ... merger with AbbVie Inc., no conference call will be held. ... the quarter ended March 31, 2015 increased to $206 ... 31, 2014. , Worldwide IMBRUVICA ® (ibrutinib) ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:4/30/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the fourth quarter and ... quarter and fiscal 2015 overview: , Revenues from ... up 33% over last year,s comparable quarter, and $202.6 ... Diluted EPS of $0.50 for the fourth quarter, up ...
Breaking Medicine Technology:Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3
... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET ) ... by the United States Patent and Trademark Office (USPTO) relating ... to treat liver disease.  Under the terms of its license ... exclusive licensee of U.S. patent 7,935,528.   The ...
... Pa., May 31, 2011 West Pharmaceutical Services, Inc. (NYSE: ... the Jefferies 2011 Global Healthcare Conference in New York, NY. ... on Monday, June 6, 2011 at 4:00 PM ET. ... well as a copy of the presentation materials, will be ...
Cached Medicine Technology:MultiCell Technologies is Granted Stem Cell Patent 2MultiCell Technologies is Granted Stem Cell Patent 3
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... Anaheim, CA (PRWEB) May 01, 2015 ... Ethos Award for the successful repositioning of its flagship ... its company brand with a new name, new logo, ... The DSA Ethos Awards are designed to identify and ... at its best. , “DSA congratulates Jusuru International ...
(Date:5/1/2015)... RESTON, Va. (PRWEB) May 01, 2015 ... the nation’s leading nonprofit authority on the use of ... served as a key contributing resource to the United ... the use of electronically readable cards in Medicare. The ... Beneficiaries and Providers ” was released to the public ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... Presentation to highlight milestones including phase III development of ... What: Horizon Therapeutics, Inc. is pleased to announce that ... M.D., Ph.D., chief executive officer, will ... including its recent completion of Series C financing, and ...
... Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study,Have Been Dosed With ... Four Have Been Dosed for More Than ... 8:00 a.m. E.T. ... at http://www.isispharm.com , CARLSBAD, Calif., Oct. 5 Isis,Pharmaceuticals, Inc. (Nasdaq: ...
... knows about the,FDA,s impending ban on children,s cold ... scramble to find other ways to alleviate their ... recently,introduced into the U.S. -- offers a safe ... According to the FDA, popular medicines such ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... U.S. may,be breathing its last gasps, as the ... Passage in the House is expected to be ... past six years, this legislation would,finally ban asbestos, ... asbestos, most deadly cancer, mesothelioma (meso), and other,asbestos-related ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the appointment ... Company,s new independent auditor effective October,2, 2007. BPM, ... the Audit Committee of the Company,s Board of ... with several,public accounting firms. BPM replaces PricewaterhouseCoopers LLP. ...
Cached Medicine News:Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 3Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 4Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 5Health News:Nosefrida Nasal Aspirator - A Parent's Alternative to Medicines on the Verge of FDA Ban 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 4
... on delicate urethral tissues. The ... coating provide nearly friction-free movement, ... easy to maintain sterility. You ... its own sterile water, avoiding ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
Active Cath is a latex, self-adhering, one piece catheter designed for extended wear. It combines a shortened latex sheath with a wide adhesive seal....
Medicine Products: